- Home
- FEBO vs ATHA Comparison
FEBO vs ATHA Comparison
Compare FEBO & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- ATHA
- Stock Information
- Founded
- FEBO 1993
- ATHA 2011
- Country
- FEBO Hong Kong
- ATHA United States
- Employees
- FEBO N/A
- ATHA N/A
- Industry
- FEBO
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- FEBO
- ATHA Health Care
- Exchange
- FEBO Nasdaq
- ATHA Nasdaq
- Market Cap
- FEBO 12.6M
- ATHA 10.6M
- IPO Year
- FEBO 2023
- ATHA 2020
- Fundamental
- Price
- FEBO $1.09
- ATHA $0.30
- Analyst Decision
- FEBO
- ATHA Buy
- Analyst Count
- FEBO 0
- ATHA 4
- Target Price
- FEBO N/A
- ATHA $11.25
- AVG Volume (30 Days)
- FEBO 8.7K
- ATHA 928.2K
- Earning Date
- FEBO 07-15-2025
- ATHA 07-31-2025
- Dividend Yield
- FEBO N/A
- ATHA N/A
- EPS Growth
- FEBO N/A
- ATHA N/A
- EPS
- FEBO N/A
- ATHA N/A
- Revenue
- FEBO $17,110,653.00
- ATHA N/A
- Revenue This Year
- FEBO N/A
- ATHA N/A
- Revenue Next Year
- FEBO N/A
- ATHA N/A
- P/E Ratio
- FEBO N/A
- ATHA N/A
- Revenue Growth
- FEBO 11.58
- ATHA N/A
- 52 Week Low
- FEBO $0.93
- ATHA $0.22
- 52 Week High
- FEBO $17.68
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- FEBO 40.32
- ATHA 45.68
- Support Level
- FEBO $1.01
- ATHA $0.29
- Resistance Level
- FEBO $1.26
- ATHA $0.32
- Average True Range (ATR)
- FEBO 0.07
- ATHA 0.02
- MACD
- FEBO -0.00
- ATHA -0.00
- Stochastic Oscillator
- FEBO 2.00
- ATHA 0.17
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.